Patents by Inventor Robert M. Carr

Robert M. Carr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030195618
    Abstract: The invention is directed to bioengineered vascular graft support prostheses prepared from cleaned tissue material derived from animal sources. The bioengineered graft prostheses of the invention are prepared using methods that preserve cell compatibility, strength, and bioremodelability of the processed tissue matrix. The bioengineered graft prostheses are used for implantation, repair, or for use in a mammalian host.
    Type: Application
    Filed: April 11, 2003
    Publication date: October 16, 2003
    Applicants: Organogenesis, Inc., Duke University School of Medicine
    Inventors: Ginger A. Abraham, Robert M. Carr, Tam Huynh, Per Otto Hagen, Mark Davies
  • Publication number: 20030171824
    Abstract: The invention is directed to bioengineered tubular graft prostheses prepared from cleaned tissue material derived from animal sources. The bioengineered graft prostheses of the invention are prepared using methods that preserve cell compatibility, strength, and bioremodelability of the processed tissue matrix. The bioengineered graft prostheses are used for implantation, repair, or for use in a mammalian host.
    Type: Application
    Filed: March 3, 2003
    Publication date: September 11, 2003
    Applicant: Organogenesis, Inc.
    Inventors: Ginger A. Abraham, Robert M. Carr
  • Publication number: 20030158607
    Abstract: This invention is directed to prosthesis, which, when implanted into a mammalian patient, serves as a functioning replacement for a body part, or tissue structure, and will undergo controlled biodegradation occurring concomitantly with bioremodeling by the patient's living cells. The prosthesis is treated so that it is rendered non-antigenic so as not to elicit a significant humoral immune response. The prosthesis of this invention, in its various embodiments, thus has dual properties. First, it functions as a substitute body part, and second, it functions as bioremodeling template for the ingrowth of host cells.
    Type: Application
    Filed: February 28, 2003
    Publication date: August 21, 2003
    Inventors: Robert M. Carr, Kimberlie D. Condon, Paul L. Termin, Janet Hardin Young
  • Patent number: 6599690
    Abstract: The invention is directed to collagenous tissues which have been treated to remove non-collagenous components such as cells, cellular debris, and other extracellular matrix components, such as proteoglycans and glycosaminoglycans, normally found in native tissues. Treatment of the tissue with alkali, chelating agents, acids and salts removes non-collagenous components from the collagenous tissue matrix while controlling the amount of swelling and dissolution so that the resultant collagen matrix retains its structural organization, integrity and bioremodelable properties. The process circumvents the need to use detergents and enzymes which detrimentally affect the cell compatibility, strength and bioremodelability of the collagen matrix. The collagenous tissue matrix is used for implantation, repair, or use in a mammalian host.
    Type: Grant
    Filed: November 30, 1999
    Date of Patent: July 29, 2003
    Assignee: Organogenesis Inc.
    Inventors: Ginger A. Abraham, Robert M. Carr, Jr., Paul D. Kemp, Ryan Mercer, Linda Baker
  • Patent number: 6572650
    Abstract: The invention is directed to bioengineered vascular graft support prostheses prepared from cleaned tissue material derived from animal sources. The bioengineered graft prostheses of the invention are prepared using methods that preserve cell compatibility, strength, and bioremodelability of the processed tissue matrix. The bioengineered graft prostheses are used for implantation, repair, or for use in a mammalian host.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: June 3, 2003
    Assignees: Organogenesis Inc., Duke University School of Medicine
    Inventors: Ginger A. Abraham, Robert M. Carr, Jr., Tam Huynh, Otto Per Hagen, Mark Davies
  • Publication number: 20020095218
    Abstract: This invention is directed to prosthesis, which, when implanted into a mammalian patient, serves as a functioning replacement for a body part, or tissue structure, and will undergo controlled biodegradation occurring concomitantly with bioremodeling by the patient's living cells. The prosthesis is treated so that it is rendered non-antigenic so as not to elicit a significant humoral immune response. The prosthesis of this invention, in its various embodiments, thus has dual properties. First, it functions as a substitute body part, and second, it functions as bioremodeling template for the ingrowth of host cells.
    Type: Application
    Filed: April 26, 2001
    Publication date: July 18, 2002
    Inventors: Robert M. Carr, Kimberlie D. Condon, Paul L. Termin, Janet Hardin Young
  • Publication number: 20020019663
    Abstract: This invention is directed to a method of treating a patient with diseased or damaged organs comprising administering to said patient a bioremodelable collagen-containing material which promotes the production of structural collagen, vascularization and epithelialization by the ingrowth of patient cells, wherein the material undergoes controlled biodegradation occurring with adequate living cell replacement such that the original implanted graft is bioremodeled by the patient's living cells.
    Type: Application
    Filed: September 7, 2001
    Publication date: February 14, 2002
    Inventors: Paul L. Termin, Robert M. Carr, Kimberlie D. Condon
  • Patent number: 6334872
    Abstract: This invention is directed to a method of treating a patient with diseased or damaged organs comprising administering to said patient a bioremodelable collagen-containing material which promotes the production of structural collagen, vascularization and epithelialization by the ingrowth of patient cells, wherein the material undergoes controlled biodegradation occurring with adequate living cell replacement such that the original implanted graft is bioremodeled by the patient's living cells.
    Type: Grant
    Filed: July 7, 1997
    Date of Patent: January 1, 2002
    Assignee: Organogenesis Inc.
    Inventors: Paul L. Termin, Robert M. Carr, Jr., Kimberlie D. Condon
  • Patent number: 5997896
    Abstract: The invention provides injectable collagen compositions that are reconstituted collagen fiber segments made from acid extracted collagen with telopeptides in a biocompatible carrier, with the collagen concentration in the composition ranging up to 200 mg/mL.
    Type: Grant
    Filed: May 11, 1998
    Date of Patent: December 7, 1999
    Assignee: Organogenesis, Inc.
    Inventors: Robert M. Carr, Jr., John F. Cavallaro, Lisa M. Bryant, David W. Donovan, Paul D. Kemp
  • Patent number: 5993844
    Abstract: The invention is directed to collagenous tissues which have been treated to remove non-collagenous components such as cells, cellular debris, and other extracellular matrix components, such as proteoglycans and glycosaminoglycans, normally found in native tissues. Treatment of the tissue with alkali, chelating agents, acids and salts removes non-collagenous components from the collagenous tissue matrix while controlling the amount of swelling and dissolution so that the resultant collagen matrix retains its structural organization, integrity and bioremodelable properties. The process circumvents the need to use detergents and enzymes which detrimentally affect the cell compatibility, strength and bioremodelability of the collagen matrix. The collagenous tissue matrix is used for implantation, repair, or use in a mammalian host.
    Type: Grant
    Filed: May 8, 1997
    Date of Patent: November 30, 1999
    Assignee: Organogenesis, Inc.
    Inventors: Ginger A. Abraham, Robert M. Carr, Jr., Paul D. Kemp, Ryan Mercer, Linda Baker
  • Patent number: 5733337
    Abstract: This invention is directed to prosthesis, which, when implanted into a mammalian patient, serve as a functioning replacement for a body part, or tissue structure, and will undergo controlled biodegradation occurring concomitantly with bioremodeling by the patient's living cells. The prosthesis of this invention, in its various embodiments, thus has dual properties. First, it functions as a substitute body part, and second, it functions as bioremodeling template for the ingrowth of host cells.
    Type: Grant
    Filed: April 7, 1995
    Date of Patent: March 31, 1998
    Assignee: Organogenesis, Inc.
    Inventors: Robert M. Carr, Jr., Paul L. Termin, Kimberlie D. Condon
  • Patent number: 5378469
    Abstract: The present invention provides improved collagen threads and methods of making and using such threads, including the production of yarn, as well as braided, knitted, and woven articles of manufacture, comprising such threads.
    Type: Grant
    Filed: October 7, 1991
    Date of Patent: January 3, 1995
    Assignee: Organogenesis, Inc.
    Inventors: Paul D. Kemp, Robert M. Carr, Jr., John G. Maresh, John Cavallaro, Jerome Gross
  • Patent number: 5256418
    Abstract: The present invention provides collagen constructs and methods of making and using such constructs. The present invention also provides tissue equivalents having improved characteristics and methods of making and using such tissue equivalents. This invention also provides methods of producing highly concentrated solutions of collagen.
    Type: Grant
    Filed: April 6, 1990
    Date of Patent: October 26, 1993
    Assignee: Organogenesis, Inc.
    Inventors: Paul D. Kemp, Robert M. Carr, Jr., John G. Maresh